Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kazuhiko Kanou is active.

Publication


Featured researches published by Kazuhiko Kanou.


Nature Reviews Drug Discovery | 2009

Community-wide assessment of GPCR structure modelling and ligand docking

Mayako Michino; Enrique Abola; Charles L. Brooks; J. Scott Dixon; John Moult; Raymond C. Stevens; Arthur J. Olson; Wiktor Jurkowski; Arne Elofsson; Slawomir Filipek; Irina D. Pogozheva; Bernard Maigret; Jeremy A. Horst; Ambrish Roy; Brady Bernard; Shyamala Iyer; Yang Zhang; Ram Samudrala; Osman Ugur Sezerman; Gregory V. Nikiforovich; Christina M. Taylor; Stefano Costanzi; Y. Vorobjev; N. Bakulina; Victor V. Solovyev; Kazuhiko Kanou; Daisuke Takaya; Genki Terashi; Mayuko Takeda-Shitaka; Hideaki Umeyama

Recent breakthroughs in the determination of the crystal structures of G protein-coupled receptors (GPCRs) have provided new opportunities for structure-based drug design strategies targeting this protein family. With the aim of evaluating the current status of GPCR structure prediction and ligand docking, a community-wide, blind prediction assessment — GPCR Dock 2008 — was conducted in coordination with the publication of the crystal structure of the human adenosine A2A receptor bound to the ligand ZM241385. Twenty-nine groups submitted 206 structural models before the release of the experimental structure, which were evaluated for the accuracy of the ligand binding mode and the overall receptor model compared with the crystal structure. This analysis highlights important aspects for success and future development, such as accurate modelling of structurally divergent regions and use of additional biochemical insight such as disulphide bridges in the extracellular loops.


Journal of Virology | 2014

The Host Protease TMPRSS2 Plays a Major Role in In Vivo Replication of Emerging H7N9 and Seasonal Influenza Viruses

Kouji Sakai; Yasushi Ami; Maino Tahara; Toru Kubota; Masaki Anraku; Masako Abe; Noriko Nakajima; Tsuyoshi Sekizuka; Kazuya Shirato; Yuriko Suzaki; Akira Ainai; Yuichiro Nakatsu; Kazuhiko Kanou; Kazuya Nakamura; Tadaki Suzuki; Katsuhiro Komase; Eri Nobusawa; Katsumi Maenaka; Makoto Kuroda; Hideki Hasegawa; Yoshihiro Kawaoka; Masato Tashiro; Makoto Takeda

ABSTRACT Proteolytic cleavage of the hemagglutinin (HA) protein is essential for influenza A virus (IAV) to acquire infectivity. This process is mediated by a host cell protease(s) in vivo. The type II transmembrane serine protease TMPRSS2 is expressed in the respiratory tract and is capable of activating a variety of respiratory viruses, including low-pathogenic (LP) IAVs possessing a single arginine residue at the cleavage site. Here we show that TMPRSS2 plays an essential role in the proteolytic activation of LP IAVs, including a recently emerged H7N9 subtype, in vivo. We generated TMPRSS2 knockout (KO) mice. The TMPRSS2 KO mice showed normal reproduction, development, and growth phenotypes. In TMPRSS2 KO mice infected with LP IAVs, cleavage of HA was severely impaired, and consequently, the majority of LP IAV progeny particles failed to gain infectivity, while the viruses were fully activated proteolytically in TMPRSS2+/+ wild-type (WT) mice. Accordingly, in contrast to WT mice, TMPRSS2 KO mice were highly tolerant of challenge infection by LP IAVs (H1N1, H3N2, and H7N9) with ≥1,000 50% lethal doses (LD50) for WT mice. On the other hand, a high-pathogenic H5N1 subtype IAV possessing a multibasic cleavage site was successfully activated in the lungs of TMPRSS2 KO mice and killed these mice, as observed for WT mice. Our results demonstrate that recently emerged H7N9 as well as seasonal IAVs mainly use the specific protease TMPRSS2 for HA cleavage in vivo and, thus, that TMPRSS2 expression is essential for IAV replication in vivo. IMPORTANCE Influenza A virus (IAV) is a leading pathogen that infects and kills many humans every year. We clarified that the infectivity and pathogenicity of IAVs, including a recently emerged H7N9 subtype, are determined primarily by a host protease, TMPRSS2. Our data showed that TMPRSS2 is the key host protease that activates IAVs in vivo through proteolytic cleavage of their HA proteins. Hence, TMPRSS2 is a good target for the development of anti-IAV drugs. Such drugs could also be effective for many other respiratory viruses, including the recently emerged Middle East respiratory syndrome (MERS) coronavirus, because they are also activated by TMPRSS2 in vitro. Consequently, the present paper could have a large impact on the battle against respiratory virus infections and contribute greatly to human health.


Infection, Genetics and Evolution | 2013

Molecular evolution of attachment glycoprotein (G) gene in human respiratory syncytial virus detected in Japan 2008–2011

Izumi Kushibuchi; Miho Kobayashi; Takashi Kusaka; Hiroyuki Tsukagoshi; Akihide Ryo; Ayako Yoshida; Haruyuki Ishii; Takeshi Saraya; Daisuke Kurai; Norio Yamamoto; Kazuhiko Kanou; Mika Saitoh; Masahiro Noda; Makoto Kuroda; Yukio Morita; Kunihisa Kozawa; Kazunori Oishi; Masato Tashiro; Hirokazu Kimura

We investigated the evolution of the C-terminal 3rd hypervariable region of G gene in the prevalent human respiratory syncytial virus (RSV) subgroups A (RSV-A) and B (RSV-B) in Japan in 2008-2011. Phylogenetic analysis and the evolutionary timescale was obtained by the Bayesian Markov Chain Monte Carlo method. All 38 RSV-A strains detected were classified into genotype NA1 and the 17 RSV-B strains detected belonged to genotypes BA and GB2. NA1 subdivided around 1998 in the present phylogenetic tree. Genotype BA subdivided around 1994. The evolutionary rates for RSV-A and RSV-B were estimated at 3.63×10⁻³ and 4.56×10⁻³ substitutions/site/year, respectively. The mean evolutionary rate of RSV-B was significantly faster than that of RSV-A during all seasons. The pairwise distance was relatively short (less than 0.06). In addition, some unique sites under positive selection were found. The results suggested that this region of the RSV strains rapidly evolved with some unique amino acid substitutions due to positive pressure.


Proteins | 2007

Fams-ace: a combined method to select the best model after remodeling all server models.

Genki Terashi; Mayuko Takeda-Shitaka; Kazuhiko Kanou; Mitsuo Iwadate; Daisuke Takaya; Akio Hosoi; Kazuhiro Ohta; Hideaki Umeyama

During Critical Assessment of Protein Structure Prediction (CASP7, Pacific Grove, CA, 2006), fams‐ace was entered in the 3D coordinate prediction category as a human expert group. The procedure can be summarized by the following three steps. (1) All the server models were refined and rebuilt utilizing our homology modeling method. (2) Representative structures were selected from each server, according to a model quality evaluation, based on a 3D1D profile score (like Verify3D). (3) The top five models were selected and submitted in the order of the consensus‐based score (like 3D‐Jury). Fams‐ace is a fully automated server and does not require human intervention. In this article, we introduce the methodology of fams‐ace and discuss the successes and failures of this approach during CASP7. In addition, we discuss possible improvements for the next CASP. Proteins 2007.


Proteins | 2007

The SKE-DOCK server and human teams based on a combined method of shape complementarity and free energy estimation.

Genki Terashi; Mayuko Takeda-Shitaka; Kazuhiko Kanou; Mitsuo Iwadate; Daisuke Takaya; Hideaki Umeyama

We participated in rounds 6–12 of the critical assessment of predicted interaction (CAPRI) contest as the SKE‐DOCK server and human teams. The SKE‐DOCK server is based on simple geometry docking and a knowledge base scoring function. The procedure is summarized in the following three steps: (1) protein docking according to shape complementarity, (2) evaluating complex models, and (3) repacking side‐chain of models. The SKE‐DOCK server did not make use of biological information. On the other hand, the human team tried various intervention approaches. In this article, we describe in detail the processes of the SKE‐DOCK server, together with results and reasons for success and failure. Good predicted models were obtained for target 25 by both the SKE‐DOCK server and human teams. When the modeled receptor proteins were superimposed on the experimental structures, the smallest Ligand‐rmsd values corresponding to the rmsd between the model and experimental structures were 3.307 and 3.324 Å, respectively. Moreover, the two teams obtained 4 and 2 acceptable models for target 25. The overall result for both the SKE‐DOCK server and human teams was medium accuracy for one (Target 25) out of nine targets. Proteins 2007.


Nature Communications | 2015

ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction

Kei Miyakawa; Satoko Matsunaga; Kazuhiko Kanou; Atsushi Matsuzawa; Ryo Morishita; Ayumi Kudoh; Keisuke Shindo; Masaru Yokoyama; Hironori Sato; Hirokazu Kimura; Tomohiko Tamura; Naoki Yamamoto; Hidenori Ichijo; Akifumi Takaori-Kondo; Akihide Ryo

APOBEC3G (A3G) is an innate antiviral restriction factor that strongly inhibits the replication of human immunodeficiency virus type 1 (HIV-1). An HIV-1 accessory protein, Vif, hijacks the host ubiquitin–proteasome system to execute A3G degradation. Identification of the host pathways that obstruct the action of Vif could provide a new strategy for blocking viral replication. We demonstrate here that the host protein ASK1 (apoptosis signal-regulating kinase 1) interferes with the counteraction by Vif and revitalizes A3G-mediated viral restriction. ASK1 binds the BC-box of Vif, thereby disrupting the assembly of the Vif–ubiquitin ligase complex. Consequently, ASK1 stabilizes A3G and promotes its incorporation into viral particles, ultimately reducing viral infectivity. Furthermore, treatment with the antiretroviral drug AZT (zidovudine) induces ASK1 expression and restores the antiviral activity of A3G in HIV-1-infected cells. This study thus demonstrates a distinct function of ASK1 in restoring the host antiviral system that can be enhanced by AZT treatment.


Journal of Virology | 2013

TMPRSS2 Is an Activating Protease for Respiratory Parainfluenza Viruses

Masako Abe; Maino Tahara; Kouji Sakai; Hiromi Yamaguchi; Kazuhiko Kanou; Kazuya Shirato; Miyuki Kawase; Masahiro Noda; Hirokazu Kimura; Shutoku Matsuyama; Hideo Fukuhara; Katsumi Mizuta; Katsumi Maenaka; Yasushi Ami; Mariko Esumi; Atsushi Kato; Makoto Takeda

ABSTRACT Here, we show that human parainfluenza viruses and Sendai virus (SeV), like other respiratory viruses, use TMPRSS2 for their activation. The membrane fusion proteins of respiratory viruses often possess serine and glutamine residues at the P2 and P3 positions, respectively, but these residues were not critical for cleavage by TMPRSS2. However, mutations of these residues affected SeV growth in specific epithelial cell lines, suggesting the importance of these residues for SeV replication in epithelia.


Journal of Bacteriology | 2007

Topology of AspT, the Aspartate:Alanine Antiporter of Tetragenococcus halophilus, Determined by Site-Directed Fluorescence Labeling

Kei Nanatani; Takashi Fujiki; Kazuhiko Kanou; Mayuko Takeda-Shitaka; Hideaki Umeyama; Liwen Ye; Xicheng Wang; Tasuku Nakajima; Takafumi Uchida; Peter C. Maloney; Keietsu Abe

The gram-positive lactic acid bacterium Tetragenococcus halophilus catalyzes the decarboxylation of L-aspartate (Asp) with release of L-alanine (Ala) and CO(2). The decarboxylation reaction consists of two steps: electrogenic exchange of Asp for Ala catalyzed by an aspartate:alanine antiporter (AspT) and intracellular decarboxylation of the transported Asp catalyzed by an L-aspartate-beta-decarboxylase (AspD). AspT belongs to the newly classified aspartate:alanine exchanger family (transporter classification no. 2.A.81) of transporters. In this study, we were interested in the relationship between the structure and function of AspT and thus analyzed the topology by means of the substituted-cysteine accessibility method using the impermeant, fluorescent, thiol-specific probe Oregon Green 488 maleimide (OGM) and the impermeant, nonfluorescent, thiol-specific probe [2-(trimethylammonium)ethyl]methanethiosulfonate bromide. We generated 23 single-cysteine variants from a six-histidine-tagged cysteineless AspT template. A cysteine position was assigned an external location if the corresponding single-cysteine variant reacted with OGM added to intact cells, and a position was assigned an internal location if OGM labeling required cell lysis. The topology analyses revealed that AspT has a unique topology; the protein has 10 transmembrane helices (TMs), a large hydrophilic cytoplasmic loop (about 180 amino acids) between TM5 and TM6, N and C termini that face the periplasm, and a positively charged residue (arginine 76) within TM3. Moreover, the three-dimensional structure constructed by means of the full automatic modeling system indicates that the large hydrophilic cytoplasmic loop of AspT possesses a TrkA_C domain and a TrkA_C-like domain and that the three-dimensional structures of these domains are similar to each other even though their amino acid sequences show low similarity.


Journal of Virology | 2017

Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry

Kazuya Shirato; Kazuhiko Kanou; Miyuki Kawase; Shutoku Matsuyama

ABSTRACT Human coronavirus 229E (HCoV-229E), a causative agent of the common cold, enters host cells via two distinct pathways: one is mediated by cell surface proteases, particularly transmembrane protease serine 2 (TMPRSS2), and the other by endosomal cathepsin L. Thus, specific inhibitors of these proteases block virus infection. However, it is unclear which of these pathways is actually utilized by HCoV-229E in the human respiratory tract. Here, we examined the mechanism of cell entry used by a pseudotyped virus bearing the HCoV-229E spike (S) protein in the presence or absence of protease inhibitors. We found that, compared with a laboratory strain isolated in 1966 and passaged for a half century, clinical isolates of HCoV-229E were less likely to utilize cathepsin L; rather, they showed a preference for TMPRSS2. Two amino acid substitutions (R642M and N714K) in the S protein of HCoV-229E clinical isolates altered their sensitivity to a cathepsin L inhibitor, suggesting that these amino acids were responsible for cathepsin L use. After 20 passages in HeLa cells, the ability of the isolate to use cathepsin increased so that it was equal to that of the laboratory strain; this increase was caused by an amino acid substitution (I577S) in the S protein. The passaged virus showed a reduced ability to replicate in differentiated airway epithelial cells cultured at an air-liquid interface. These results suggest that the endosomal pathway is disadvantageous for HCoV-229E infection of human airway epithelial cells; therefore, clinical isolates are less able to use cathepsin. IMPORTANCE Many enveloped viruses enter cells through endocytosis. Viral spike proteins drive the fusion of viral and endosomal membranes to facilitate insertion of the viral genome into the cytoplasm. Human coronavirus 229E (HCoV-229E) utilizes endosomal cathepsin L to activate the spike protein after receptor binding. Here, we found that clinical isolates of HCoV-229E preferentially utilize the cell surface protease TMPRSS2 rather than endosomal cathepsin L. The endosome is a main site of Toll-like receptor recognition, which then triggers an innate immune response; therefore, HCoV-229E presumably evolved to bypass the endosome by entering the cell via TMPRSS2. Thus, the virus uses a simple mechanism to evade the host innate immune system. Therefore, therapeutic agents for coronavirus-mediated diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), should target cell surface TMPRSS2 rather than endosomal cathepsin.


Proteins | 2005

Protein structure prediction in CASP6 using CHIMERA and FAMS

Mayuko Takeda-Shitaka; Genki Terashi; Daisuke Takaya; Kazuhiko Kanou; Mitsuo Iwadate; Hideaki Umeyama

In CASP6, the CHIMERA‐group predicted full‐atom models of all targets using SKE‐CHIMERA, a Web‐user interface system for protein structure prediction that allows human intervention at necessary stages; we used a lot of information from our own data and from publicly available data. Using SKE‐CHIMERA, we iterated manual step (template selection and alignment by the in‐house program CHIMERA) and automatic step (three‐dimensional model building by the in‐house program FAMS). The official CASP6 assessment showed that CHIMERA‐group was one of the most successful predictors in homology modeling, especially for FR/H (Fold Recognition/Homologous). In this article, we introduce the method of CHIMERA‐group and discuss its successes and failures in CASP6. Proteins 2005;Suppl 7:122–127.

Collaboration


Dive into the Kazuhiko Kanou's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Makoto Takeda

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge